As Dr T has pointed out, when comparing bisantrene with other FTO inhibitors, the clinical history or lack thereof is more important than the precise amount by which bisantrene is more potent than its "peers".
I think it's sufficient to say in the "bisantrene among peers" section that bisantrene ticks both boxes, and that brequinar has unpredictable dosing and dangerous auto immune side effects.
- Forums
- ASX - By Stock
- RAC
- RAC Primer
RAC Primer, page-164
-
-
- There are more pages in this discussion • 358 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M |
Open | High | Low | Value | Volume |
$1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 92 | $1.83 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.87 | 3472 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5300 | 1.810 |
1 | 8722 | 1.800 |
1 | 1059 | 1.790 |
4 | 10695 | 1.750 |
2 | 8147 | 1.730 |
Price($) | Vol. | No. |
---|---|---|
1.865 | 3472 | 1 |
1.880 | 2500 | 1 |
1.940 | 5148 | 2 |
1.945 | 3014 | 1 |
1.950 | 12000 | 1 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |